Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041976 | 1.00 | TGFBR1 (0.51) | TGFBR1GSK3BMAPK14DYRK1AGRM2 | |
| SCHEMBL18041918 | 0.92 | TGFBR1 (0.61) | TGFBR1GSK3BMAPK14DYRK1ATGFBR2 | |
| SCHEMBL18041698 | 0.87 | TGFBR1 (0.53) | TGFBR1GSK3BMAPK14DYRK1ATGFBR2 | |
| SCHEMBL18041870 | 0.87 | TGFBR1 (0.56) | TGFBR1GSK3BMAPK14DYRK1AGRM2 | |
| SCHEMBL29676985 | 0.87 | TGFBR1 (0.56) | TGFBR1GSK3BMAPK14DYRK1AGRM2 | |
| SCHEMBL18041603 | 0.85 | TGFBR1 (0.59) | TGFBR1GSK3BMAPK14DYRK1ATGFBR2 | |
| SCHEMBL18041605 | 0.83 | TGFBR1 (0.59) | TGFBR1MAPK14DYRK1ATGFBR2PDE4A | |
| SCHEMBL15638144 | 0.79 | TGFBR1 (0.59) | TGFBR1DYRK1AGRM2TGFBR2PDE4A | |
| SCHEMBL19806362 | 0.78 | TGFBR1 (0.47) | TGFBR1DYRK1AGRM2TGFBR2PDE4A | |
| SCHEMBL18041938 | 0.77 | TGFBR1 (0.57) | TGFBR1GSK3BMAPK14DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885GSK3B 33/4885MAPK14 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.